Lunit and Rebellion Sign MOU for Global AI Business Development Collaboration

"Global Leap Forward Through Medical AI Innovation"

On October 15, Lunit, a medical artificial intelligence (AI) company, announced that it has signed a Memorandum of Understanding (MOU) with Rebellion, an AI semiconductor company, to officially begin collaboration on medical AI innovation and global AI business development.

Rebellion is a company that develops AI semiconductors (NPUs) optimized for inference operations. By combining Lunit’s specialized medical AI models with Rebellion’s NPU-based platform, the two companies have agreed to lead innovation in the domestic vertical AI industry and to realize global market leadership.

Kim Kwangjung, Head of Business at Rebellion (from left), Park Sunghyun, CEO, Seo Beomseok, CEO of Lunit, and Yoo Sungwon, CTO, are posing for a commemorative photo after signing a Memorandum of Understanding (MOU) for global AI business development at Lunit headquarters in Gangnam-gu, Seoul, on the 30th of last month. Lunit

To start, the two companies will participate in various government projects as a consortium, integrating Lunit’s differentiated medical AI models with Rebellion’s low-power, high-performance NPUs to implement nationwide medical services. They aim to dramatically improve accessibility, cost efficiency, and quality in medical AI. In particular, by joining government projects as a consortium, they plan to maximize the operational efficiency of medical science-specialized AI models-among the most widely used vertical AI models-and contribute to the activation of the vertical AI sector.

In addition, as part of their global business development cooperation, the two companies will jointly promote the export of domestically developed AI solutions. They will co-market an appliance-type product that integrates Lunit’s medical AI models with Rebellion’s NPUs. By combining Lunit’s experience in providing AI diagnostic services in 65 countries worldwide and Rebellion’s expertise in supplying NPUs to Aramco data centers, they aim to create strong synergy. Based on this, they plan to actively participate in public healthcare projects such as national cancer screening programs in other countries, thereby pursuing overseas market entry and the development of new business models.

This collaboration is expected to accelerate the growth and expansion of the medical AI industry, and to help build a more sustainable Korean healthcare sector based on the latest AI technologies, thereby contributing to global advancement and improved public health. Furthermore, the companies plan to go beyond general-purpose models to realize specialized AI models and services that have meaningful impact on people’s everyday lives.

Seo Beomseok, CEO of Lunit, said, “This collaboration marks a significant turning point for Lunit’s medical AI technology to expand into a broader industrial ecosystem. The combination of Lunit’s precision diagnostic algorithms and Rebellion’s high-performance NPUs will drive innovation in the domestic vertical AI industry and deliver tangible medical benefits to public healthcare projects worldwide.”

Park Seonghyeon, CEO of Rebellion, stated, “Rebellion has accumulated the technology and experience to efficiently and reliably operate specialized AI services based on NPUs. By partnering with Lunit, the leading representative of Korean medical AI, we aim to help build accessible AI medical services for the Korean public and, furthermore, create new success stories in the global public sector.”